Telix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in recurrent high-grade glioma. The targeted radiation therapy, combined with ...

Researchers from the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) have described a new mechanism ...

In a physics first, a team including scientists from the National Institute of Standards and Technology (NIST) has created a ...

Leaders from Methodist University and Cape Fear Valley Health gathered with the community April 15 to celebrate the final ...

Stubbs & Wootton and Maus & Hoffman are set to kick off their popular season-ending sales with deals up to 50% off.

Raffles will be in support of the Kids with Cancer Society, Ben Stelter Foundation and Alberta Cancer Foundation ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

The quest for more effective cancer radiotherapy continues apace, with Telix Pharmaceuticals (ASX:TLX) today reporting “encouraging” preliminary results from its phase II study to treat recurrent high ...

The old Gauhati Medical College Hospital (GMCH) is set to be demolished to make way for a state-of-the-art 3,000-bed medical facility.

IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam ...